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Aortic stiffening precedes onset of heart
failure with preserved ejection fraction
in patients with asymptomatic diastolic
dysfunction
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Abstract
Background: Identifying which patients with diastolic dysfunction will progress to heart failure with preserved
ejection fraction (HFpEF) remains challenging. The goal of this study is to determine whether increased vascular
stiffness as identified on 2D transthoracic echocardiography (TTE) serves as a biomarker for the development of
HFpEF in patients with diastolic dysfunction.
Methods: The study design is a matched retrospective case–control study. Subjects with diastolic dysfunction were
divided into two groups based on whether they had a clinical diagnosis of HFpEF. The two groups were matched
based on age, gender, race and body surface area, resulting in 77 matched pairs (n = 154). Data from the first TTE
that documented diastolic dysfunction prior to the development of HFpEF was extracted along with baseline
demographic and clinical data. Indices of vascular stiffness were measured and compared. A sub-group analysis
was performed to compare diabetic subjects in Group 1 (n = 43) to those in Group 2 (n = 21).
Results: Group 1 had significantly decreased aortic distensibility as measured on the initial TTE when compared
to Group 2 (1.9 ± 1.0 vs. 2.8 ± 1.8 cm2dyne−110−3, p = 0.01). In the diabetic subset, Group 1 had significantly less
aortic strain (6.9 ± 3.3 vs. 9.7 ± 5.6%, p = 0.02) and aortic distensibility (1.8 ± 1.0 vs. 3.5 ± 2.6 cm2dyne−110−3, p = 0.02)
compared to Group 2. Other indices of vascular stiffness did not differ significantly between groups.
Conclusions: This study demonstrates that increased proximal aortic stiffness is associated with the development
of HFpEF in patients with asymptomatic diastolic dysfunction. Larger prospective studies are needed to further
investigate this relationship.
Keywords: Heart Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Diabetes, Echocardiography,
Cardiomyopathy, Biomarker
Background
Diastolic dysfunction is known to be an important
contributor to the development of heart failure with pre-
served ejection fraction (HFpEF) [1]. The pathophysio-
logic mechanisms that contribute to the continuum
between diastolic dysfunction and HFpEF have yet to
be fully elucidated. Patients with HFpEF have been
shown to have arterial stiffening beyond that associated
with normal aging and hypertension [2]. The recoil of
the ascending aorta during each cardiac cycle may fa-
cilitate early diastolic left ventricular filling [3]. Aortic
stiffening, as indicated by decreased aortic distensibil-
ity, has been associated with more severe symptoms of
heart failure in patients with HFpEF [4]. We therefore
hypothesize that increased vascular stiffness in the set-
ting of diastolic dysfunction is associated with the de-
velopment of HFpEF.
Hypertension, coronary artery disease (CAD), obesity,
atrial fibrillation (AF), chronic kidney disease (CKD) and
diabetes mellitus (DM) have all been shown to be
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associated with HFpEF [5–8]. A recent systematic meta-
analysis of 27 studies found a significant correlation
between arterial stiffness and diastolic dysfunction. Even
though it has been speculated that diastolic dysfunction
and arterial stiffness may be an important mechanism in
the development of HFpEF in these patient populations
[9], there has been no study to date that has correlated
arterial or aortic stiffness and diastolic dysfunction with
the development of HFpEF. DM in particular has been
shown to be an independent predictor of morbidity and
mortality in patients with heart failure, with the relative
risk of cardiovascular death or heart failure hospitalization
conferred by DM greater in patients with HFpEF com-
pared to heart failure with reduced ejection fraction [10].
One hypothesis is that increased advanced glycation end
product deposition and collagen cross-linking in the
diabetic myocardium leads to endothelial dysfunction and
increased vascular stiffness, thereby increasing cardiac
afterload and myocardial oxygen requirements, ultimately
leading to diastolic dysfunction and the subsequent devel-
opment of HFpEF [11].
Pulse-wave velocity, as measured by applanation to-
nometry, remains the gold-standard non-invasive
method for measuring vascular stiffness. Velocity-
encoded magnetic resonance imaging (MRI) has also
been shown to have excellent correlation with invasive
hemodynamic measurements of aortic stiffness [12]. In
addition, non-invasive measurement of aortic distensibil-
ity using TTE has been shown to have a high degree of
accuracy when compared with invasive measurements in
different populations [12, 13]. TTE is widely available at
most medical centers and measurements of vascular
stiffness can be performed from a routine comprehen-
sive TTE without the need to follow special protocols or
obtain additional images, making it an attractive alterna-
tive approach to evaluating aortic stiffness in subjects at
risk for developing HFpEF.
The goal of this study is to determine whether in-
creased vascular stiffness serves as a biomarker for the
subsequent development of HFpEF in patients with dia-
stolic dysfunction and whether this can be identified on
TTE. We hypothesize that those patients who progress
from asymptomatic diastolic dysfunction to HFpEF, both
diabetic and non-diabetic, have a greater degree of vas-
cular stiffness at baseline compared to those that remain
asymptomatic.
Methods
Study design and patient selection
The study design is a matched case–control study in
which data was retrospectively reviewed and collected.
The study protocol was approved by the Medical College
of Wisconsin Institutional Review Board. Human subject
research data was de-identified and stored electronically
on a secure, password-protected computer server (RED-
Cap). REDCap servers are securely housed in an on-site
limited access data center managed by the Medical
College of Wisconsin. All web-based information trans-
mission is encrypted. The data is stored on a private,
firewall-protected network. All users are given individual
user IDs and passwords and their access is restricted on
a role-specific basis. REDCap was developed specifically
around HIPAA-security guidelines and is implemented
and maintained per Medical College of Wisconsin
guidelines.
The echocardiogram database at Froedtert Memorial
Lutheran Hospital (FMLH) was used to screen TTEs be-
tween 7/1/2003 and 7/1/2013. The search terms in-
cluded (1) diastolic dysfunction and (2) preserved
ejection fraction (EF > 50%) and excluded (1) systolic
dysfunction, (2) normal diastolic function, (3) E/A fu-
sion, (4) mitral valve abnormalities, (5) severe aortic
stenosis, (6) severe mitral regurgitation, (7) annuloplasty
and/or (8) bioprosthetic valves. After accounting for ser-
ial studies, 561 subjects qualified for the study. Subjects
were further excluded if they had missing clinical data
(n = 63) in the EHR, any serial TTE report that included
an EF of <50% (n = 40), non-diagnostic echocardiograms
(n = 10), or if they had previously undergone heart trans-
plantation (n = 1).
Among the remaining subjects (n = 447), the electronic
health record (EHR) was reviewed to identify those sub-
jects who had heart failure with preserved ejection frac-
tion. Subjects were assigned to Group 1 (n = 107) if their
EHR contained an ICD-9 diagnosis of congestive heart
failure and clinical documentation of at least one of the
following signs or symptoms of heart failure by the end
of the study period: shortness of breath, weight gain,
orthopnea, paroxysmal nocturnal dyspnea or increased
leg swelling. Subjects were placed into Group 2 (n = 340)
if they remained free of heart failure throughout the
study period. After information on gender, race, age and
body surface area (BSA) was collected, the subjects were
optimally matched for these variables to yield 77
matched pairs (n = 154) of subjects which were ultim-
ately included in our study (Fig. 1).
For each subject, TTE reports were screened in a
retrospective fashion until the earliest study that docu-
mented diastolic dysfunction was identified, from which
echocardiographic data was extracted. Echocardio-
graphic data was initially extracted from the clinical
report which was generated by a board-certified
cardiologist. This data included: blood pressure (BP), left
ventricular posterior wall thickness at end-diastole
(LVPWd) and end-systole (LVPWs), left ventricular (LV)
mass, LV mass index, LV ejection fraction (LVEF) as
measured by Simpson’s equation, fractional shortening
(FS), LV internal diameter at end-diastole (LVIDd) and
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end-systole (LVIDs), LV end-diastolic volume (LVEDV)
and index, LV end-systolic volume (LVESV) and index,
relative wall thickness (RWT), left atrial linear dimen-
sion, left atrial volume index, mitral peak E velocity, mi-
tral peak A velocity, E/A ratio, stroke volume (SV) and
stroke volume index (SVI). Left ventricular volumes
(EDV and ESV) were calculated using the biplane method
of disks (modified Simpson’s rule). SV, LVEF and FS were
determined based on the American Society of Echocardi-
ography/European Association of Cardiovascular Imaging
(ASE/EACVI) guidelines [14] and reported in Table 1.
Diastolic function was determined and graded by the
interpreting cardiologist according to the recommenda-
tion of the American Society of Echocardiography 2002
and 2009 guidelines. The 2002 guidelines identified dia-
stolic dysfunction as having a lower E than A-wave vel-
ocity with a prolonged isovolumic relaxation time and
shortened deceleration time [15]. Mitral annular tissue e’
and a’ velocities were not routinely measured or reported
until 2009 when diastolic function grading was further
defined as: normal diastolic function: E/A ≥1, average
e’ >9 cm/s; mild diastolic dysfunction: E/A < 1, aver-
age e’ ≤ 9 cm/s, moderate diastolic dysfunction: E/A ≥
1, average e’ ≤ 9 cm/s, severe diastolic dysfunction: E/
A ≥ 2, average e’ ≤ 9 [16]. Because mitral annular tis-
sue velocities were not included on the reports until
2009, we did not report this data in the study.
Additional clinical data including hypertension, CAD,
DM, AF, CKD (estimated GFR <60 mL/min/1.73 m2 for
3 months or more), alcohol and tobacco use, N-terminal
pro-hormone brain natriuretic peptide (NT-proBNP)
level, glomerular filtration rate (GFR, estimated by the
CKD-EPI equation [17]), and data on medication use
(beta blockers, calcium channel blockers, ACE inhibitors
and angiotensin receptor blockers) was extracted from
the EHR at FMLH.
Assessment of arterial and aortic stiffness
From the earliest TTE documenting diastolic dysfunc-
tion in study subjects and prior to Group 1 subjects
Fig. 1 Flow diagram of study. Flow diagram illustrating method of subject selection, including exclusion and matching criteria
Table 1 Study calculations [12, 34–37]
Variable Formula
Pulse Pressure (PP; mmHg) systolic blood pressure (SBP) – diastolic
blood pressure (DBP)
Diastolic Wall Strain (%) (LVPWs-LVPWd)*100/LVPWs
End Systolic Pressure (mmHg) 0.9*SBP
Arterial Stiffness (mmHg/mL/m2) PP/SVI
Arterial Elastance (mmHg/mL) ESP/SV
Aortic Strain (%) (AoS-AoD)*100/AoD
Aortic Distensibility (cm2
dyne−110−3)
2* [(AoS-AoD)/(AoD*PP)] * 1000
Relative Wall Thickness (cm) 2*(LVPWd)/LVIDd
LV Mass (g) 0.8* [1.04 * (IVSd + LVIDd + LVPWd) 3 -
LVIDd3] + 0.6 g
Fractional Shortening (%) (LVIDd-LVIDs)/LVIDd*100
Stroke Volume (mL) EDV - ESV
Ejection Fraction (%) (SV/EDV) * 100
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developing heart failure, the dimensions of the ascending
aorta were measured. Ascending aortic diameters were
measured three centimeters above the aortic valve at
end-diastole (AoD) and end-systole (AoS) in the 2D
parasternal view (Fig. 2). These measurements were used
to calculate aortic distensibility and aortic strain using
formulas reported in Table 1. Arterial stiffness and arter-
ial elastance were calculated as reported in Table 1 and
included the SV as determined from the same TTE that
was used to measure aortic dimensions.
Additional calculations
The following calculations that were not included in the
clinical report were performed, as outlined in Table 1:
pulse pressure (PP), diastolic wall strain (DWS), end sys-
tolic pressure (ESP), arterial stiffness, arterial elastance,
aortic strain, aortic distensibility and relative wall thick-
ness (RWT). Missing blood pressure recordings at the
time of the earliest echocardiogram documenting dia-
stolic dysfunction prevented the calculation of some in-
dices of vascular stiffness in 48/77 subjects in Group 1
and 28/77 subjects in Group 2.
For reference, we used previous literature that pub-
lished mean adult values for aortic distensibility (in
cm2dyne−110−3) and aortic strain (%) in control subjects
(10 ± 5.1 and 18 ± 8.0, respectively), hypertensive sub-
jects (3.1 ± 1.5 and 11 ± 7.0, respectively), diabetic sub-
jects (5.1 ± 2.8 and 9 ± 3.0, respectively) and subjects
with both hypertension and diabetes (2.0 ± 0.9 and 8 ±
3.0, respectively) [18].
Statistical analysis
The data analysis was performed using Statistical Ana-
lysis System (SAS) software, version 9.3. Continuous var-
iables are expressed in the Tables as mean ± standard
deviation and categorical variables as a percentage. For
the matched pairs in our study (Group 1 vs. Group 2),
McNemar’s statistic was used to compare qualitative var-
iables and a one-sample t-test was used to compare
quantitative variables. A p-value of <0.0125 was consid-
ered statistically significant, based on the Bonferroni cor-
rection for multiple comparisons.
We performed a multiple logistic regression analysis
to determine whether aortic distensibility is associated
with higher predictive risk when adjusting for age, gen-
der, race, BSA, hypertension, DM and CKD. To calculate
the optimal cut-off value for aortic distensibility, we fit a
simple logistic regression and generated a receiver
operating characteristic (ROC) curve to achieve the
highest possible level of sensitivity and specificity, and to
maximize the area under the curve (AUC).
We also performed simple linear regressions, eliminat-
ing outliers more than two standard deviations outside
of the mean, to evaluate whether aortic distensibility is
correlated to other clinical or echocardiographic param-
eters, specifically age, gender, race, body surface area,
hypertension, DM, CKD, LV mass, LV mass index, LV
internal diameter end-diastole, LV-end diastolic volume
and index, relative wall thickness and E/A velocity.
An unmatched sub-group analysis was also performed
to compare the diabetic patients in each group (Group 1
vs. Group 2). A one-way analysis of variance (ANOVA)
was used to compare the differences between groups. A
p-value of <0.05 was considered statistically significant
for the sub-group analysis.
Results
Baseline characteristics
The baseline characteristics of the two groups are shown
in Table 2. Subjects in Group 1 had significantly more
hypertension (p = 0.02), DM (p = 0.0002), CAD (p =
0.01), and AF (p = 0.003), and subjects in Group 1 had
significantly lower GFRs (p = 0.002) and significantly
Fig. 2 Ascending aortic diameter measurements. Ascending aortic diameters were measured three centimeters above the aortic valve at end-
diastole (AoD) and end-systole (AoS) in the 2D parasternal view
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more clinical diagnoses of CKD (p < 0.0001) compared
to those in Group 2.
In the overall cohort, there were no significant differ-
ences between the number of patients on beta blockers,
calcium channel blockers, ACE inhibitors or angiotensin
receptor blockers in Group 1 versus Group 2 (Table 2).
Echocardiographic measurements
The echocardiographic measurements of the two groups
are shown in Table 3. Group 1 had significantly in-
creased left ventricular posterior wall thickness at end-
diastole (p = 0.03) and end-systole (p = 0.0001), as well as
increased left ventricular mass (p = 0.0004), left ventricu-
lar mass index (p = 0.001), left ventricular internal
diameter at end-diastole (p = 0.006), and left ventricular
internal diameter at end-systole (p = 0.02) compared to
Group 2. Group 1 also had significantly increased left
atrial linear dimension (p = 0.028) and mitral peak A vel-
ocity (p = 0.048) compared to group 2. There were no
significant differences in diastolic wall strain (p = 0.23).
No significant differences were observed with respect to
other TTE measurements including severity of diastolic
dysfunction (Table 3).
Assessment of arterial and aortic stiffness
Group 1 (n = 29) had a significant decrease in aortic
distensibility compared to Group 2 (n = 48; p = 0.01). No
significant differences were observed with respect to arter-
ial stiffness, arterial elastance and aortic strain (Table 4).
To further explore the predictive value of decreased
aortic distensibility as an independent risk factor for the
development of HFpEF, we performed a multiple logistic
regression analysis corrected for age, BSA, gender, race,
HTN, DM and CKD. The measure of aortic distensibility
was a significant predictor of the development of HFpEF
[odds ratio = 0.61 and 95% confidence interval (0.39–0.96)].
ROC curves were generated for aortic distensibility as
an indicator of future HFpEF development. If aortic dis-
tensibilty was not included in the model but all other in-
dependent variables (age, BSA, gender, race, HTN, DM
and CKD) remained the same, the area under the ROC
curve was 0.796. Adding aortic distensibility to the pre-
dictive model boosted the area under the curve to 0.815.
Therefore, at the time diastolic dysfunction is first
detected by echocardiogram, the addition of aortic
distensibilty increases the predictive value of the under-
lying co-morbidities for HFpEF development. To deter-
mine an optimal cutoff for aortic distensibility, we fit a
simple logistic regression to arrive at a cutoff of 1.84
cm2dyne−110−3 with 62.1% sensitivity and 68.8% specifi-
city (Fig. 3).
Furthermore, using simple linear regressions that
eliminated outliers more than two standard deviations
outside of the mean, aortic distensibility was poorly
correlated to age (r2 = 0.007), gender (r2 = 0.003), race
(r2 = 0.004), BSA (r2 = 0.00002), hypertension (r2 =
0.11), DM (r2 = 0.02), CKD (r2 = 0.08), LV mass (r2 =
0.04), LV mass index (r2 = 0.05), LV internal diameter
end-diastole (r2 = 0.03), LV end-diastolic volume (r2 =
0.03), LV end-diastolic volume index (r2 = 0.04), rela-
tive wall thickness (r2 = 0.03), and E/A velocity (r2 =
0.07).
Diabetic sub-group analysis
A sub-group analysis was performed to compare diabetic
subjects in Group 1 (n = 43) to diabetic subjects in
Group 2 (n = 21). There were no significant differences
observed between groups in terms of age, gender, race,
BSA, tobacco use, alcohol use, CAD, hypertension, AF
or cardiac medication usage (Table 5). The vascular
stiffness measurements, as in the main cohort, were
limited by missing blood pressure recordings. Despite
this, Group 1 (n = 43) was noted to have significantly
decreased aortic strain compared to Group 2 (n = 9;
p = 0.02). Aortic distensibility was also significantly
Table 2 Baseline characteristics






Age (years) 68.6 ± 9.9 68.5 ± 9.9 0.96




Body Surface Area (m2) 1.97 ± 0.31 1.93 ± 0.24 0.31
Tobacco Use (%) 56.2 60.3 0.61
Alcohol Use (%) 49.3 58.0 0.27
Hypertension (%) 88.3 72.7 0.02








NT-proBNP (pg/mL) 9810 ± 14308 2148 ± 3026 0.07
GFR (mL/min/1.73 m2) 44.8 ± 20.0 57.9 ± 23.6 0.002
Systolic BP (mmHg) 145.9 ± 29.7 140.9 ± 21.0 0.73
Diastolic BP (mmHg) 70.7 ± 15.7 74.6 ± 10.9 0.37
Pulse Pressure (mmHg) 75.6 ± 21.5 66.3 ± 16.7 0.17








Note: Continuous data expressed as mean ± standard deviation. Categorical
variables expressed as percentage
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decreased in Group 1 (n = 17) compared to Group 2
(n = 14; p = 0.02). Differences in arterial stiffness and
arterial elastance did not reach statistical significance
(Table 6).
Discussion
Our study found that in subjects with asymptomatic
diastolic dysfunction, decreased aortic distensibility
identified on TTE is associated with an increased risk
of developing HFpEF compared to similar subjects
with normal aortic distensibility on TTE. These find-
ings extend to the diabetic population with asymp-
tomatic diastolic dysfunction, in which both decreased
aortic distensibility and aortic strain were shown to
precede the development of HFpEF.
Our findings can be explained by the following patho-
physiologic model, initially proposed by Massie in 2003:
as the aorta becomes less elastic in the setting of arterio-
sclerosis, aging and hypertension, parallel structural
changes of hypertrophy and fibrosis occur in the cardiac
Table 3 Transthoracic echocardiogram measurements
Measurement Group 1: HFpEF (n = 77) Group 2: Diastolic Dysfunction (n = 77) P-value (matched pairs only)
LV posterior wall thickness end-diastole (cm) 1.20 ± 0.25 - (77) 1.11 ± 0.22 - (77) 0.03
LV posterior wall thickness end-systole (cm) 1.85 ± 0.38 - (75) 1.64 ± 0.26 - (72) 0.0001
LV mass (g) 217.9 ± 72.7 - (72) 177.9 ± 58.5 - (74) 0.0004
LV mass index (g/m2) 110.9 ± 34.5 - (44) 91.3 ± 26.8 - (71) 0.001
LVEF – Simpson’s (%) 61.8 ± 6.37 - (59) 60.3 ± 5.52 - (66) 0.25
Fractional shortening index (%) 33.5 ± 9.36 - (76) 34.5 ± 10.3 - (74) 0.48
LV internal diameter end-diastole (cm) 4.67 ± 0.70 - (77) 4.40 ± 0.57 - (76) 0.006
LV internal diameter end-systole (cm) 3.09 ± 0.60 - (77) 2.88 ± 0.61 - (76) 0.02
LV end-diastolic volume (mL) 87.8 ± 34.5 - (63) 84.9 ± 30.4 - (67) 0.99
LV end-diastolic volume index (mL/m2) 47.6 ± 16.1 - (21) 57.6 ± 17.3 - (17) 0.90
Diastolic Wall Strain (%) 34.0 ± 12.0 - (75) 32.0 ± 9.0 - (72) 0.23
LV end-systolic volume (mL) 35.3 ± 16.0 - (60) 33.5 ± 12.7 - (68) 0.83
LV end-systolic volume index (ml/m2) 18.8 ± 8.45 - (20) 21.8 ± 7.84 - (17) 0.90
Relative wall thickness (cm) 0.57 ± 0.16 - (23) 0.50 ± 0.08 - (16) 0.97
Left atrial linear dimension (cm) 4.10 ± 0.64 - (76) 3.89 ± 0.60 - (77) 0.03
Mitral peak E velocity (m/s) 1.09 ± 0.28 - (74) 1.01 ± 0.26 - (77) 0.052
Mitral peak A velocity (m/s) 0.89 ± 0.32 - (73) 0.79 ± 0.25 - (75) 0.048
E/A ratio 1.37 ± 0.60 - (72) 1.36 ± 0.48 - (73) 0.68
Ascending aortic root diameter end-diastole (cm 3.08 ± 0.39 - (75) 3.04 ± 0.43 - (72) 0.54
Ascending aortic root diameter end-systole (cm) 3.31 ± 0.37 - (75) 3.29 ± 0.42 - (72) 0.86
Stroke volume (mL) 81.4 ± 24.5 - (28) 77.7 ± 17.1 - (38) 0.82
Stroke volume index (mL/m2) 41.1 ± 13.3 - (27) 40.4 ± 10.5 - (38) 0.74
LV end systolic pressure (mmHg) 131.4 ± 26.7 - (29) 126.9 ± 18.9 - (49) 0.73
Mild Diastolic Dysfunction (%) 24.7 9.1 0.04*
Moderate Diastolic Dysfunction (%) 71.4 83.1
Severe Diastolic Dysfunction (%) 3.9 7.8
Note: Continuous data expressed as mean ± standard deviation. Categorical variables expressed as percentage. Group size is listed in parentheses
*p-value calculated using conditional logistic regression with two degrees of freedom
Table 4 Markers of vascular stiffness
Variable Group 1: HFpEF (n = 77) Group 2: Diastolic Dysfunction (n = 77) P-value
Arterial Stiffness (mmHg/mL/m2) 2.0 ± 0.69 - (22) 1.7 ± 0.52 – (30) 0.49
Arterial Elastance (mmHg/mL) 1.7 ± 0.50 - (22) 1.7 ± 0.40 – (30) 0.80
Aortic Strain (%) 7.5 ± 3.6 – (75) 8.6 ± 4.2 – (72) 0.22
Aortic Distensibility (cm2dyne−110−3) 1.9 ± 1.0 – (29) 2.8 ± 1.8 – (48) 0.01
Note: All data expressed as mean ± standard deviation. Group size is listed in parentheses
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myocardium because of increased vascular load, leading
to decreased myocardial compliance, impaired relaxation
and left ventricular diastolic dysfunction. Over time,
chronically elevated diastolic pressures in the left ven-
tricle lead to the development of symptomatic heart fail-
ure [19]. Gillebert highlighted the concept of load-
dependent diastolic dysfunction, a physiologic process
by which afterload that crosses a particular threshold
causes slow and incomplete myocardial relaxation,
resulting in elevated filling pressures and ultimately con-
gestive heart failure [20]. In 2011, Borlaug and Kass fur-
ther refined the model by incorporating the concept of
ventricular-arterial coupling into the pathophysiological
development of HFpEF. In brief, the net interaction be-
tween ventricular and arterial stiffness impacts cardiac
function and dictates the development of symptoms due
to a greater dependence on systolic pressure for coron-
ary flow and increased ischemia for a given drop in sys-
tolic blood pressure, which is exacerbated by exercise in
patients with HFpEF [21]. In support, Ikonomidis et al.
found that impaired left ventricular untwisting is
associated with increased arterial stiffness, increased
markers of collagen turnover and decreased coronary
flow reserve in subjects with hypertensive heart disease,
suggesting that impaired ventricular-arterial coupling
precedes the development of HFpEF [22]. While brachial
pulse pressure has historically been used as a crude sur-
rogate for arterial stiffness, Naka et al. suggested in 2015
that the prognostic role of central aortic pressure, a po-
tentially more robust marker of risk in heart failure,
needs to be further investigated [23].
Chirinos et al. also demonstrated the concept of pulsa-
tile load, which suggests that wave reflections that arise
in peripheral arteries and return to the proximal aorta
during mid-to-late systole are important contributors to
left ventricular afterload. Their study demonstrated that
increased arterial wave reflections during mid-to-late
systole are associated with an increased risk for cardio-
vascular events and the development of heart failure
symptoms [24]. Thus, it is possible that increased pulsa-
tile load over time results in chronically elevated pres-
sures in the ascending aorta, resulting in increased
aortic stiffness and left ventricular afterload, and ultim-
ately the development of HFpEF by inducing structural
and functional changes in the left ventricular myocar-
dium as described in the literature above.
When measuring proximal aortic stiffness, it is import-
ant to account for the dynamic effect of pulsatile load
on the compliance of the aorta [25]. The equation used
to measure proximal aortic distensibility includes pulse
Fig. 3 ROC curve for optimal aortic distensibility cut-off. ROC curve showing optimal aortic distensibility cut-off of 1.8 cm2dyne−110−3, with 62.1%
sensitivity and 68.8% specificity. The AUC of the ROC curve is 0.671
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pressure as well as aortic strain; therefore, it accounts
for a more physiologic and continuous measurement of
aortic stiffness [12]. Even though other reliable non-
invasive methods such as brachial-ankle pulse wave vel-
ocities take into account the peripheral vascular bed
[26], the advantage of measuring proximal aortic stiff-
ness from TTE is that it can still be assessed at the same
time diastolic dysfunction is discovered in an individual
subject without the need for additional testing.
Increased arterial stiffness has previously been corre-
lated with diastolic dysfunction [27–29]. Namba et al.
showed evidence in a cross-sectional study that cardio-
ankle vascular index was independently associated with
LV diastolic dysfunction in subjects with cardiovascular
disease [27]. The study findings reported by Seeland et
al. and Alba et al. support the significant associations be-
tween pathologic pulse wave velocities and the preva-
lence of diastolic dysfunction in women [28, 29].
Therefore, the increased correlation between arterial
stiffness and asymptomatic diastolic dysfunction in sub-
jects may also account for the lack of statistical signifi-
cance between the two groups, each with diastolic
dysfunction in our study. However, the statistically sig-
nificant difference in aortic distensibility found between
the two groups in our study suggests that even though
increased peripheral arterial stiffness is associated with
asymptomatic diastolic dysfunction, the additional con-
tribution of increased proximal aortic stiffness may be
required for the progression from asymptomatic dia-
stolic dysfunction to HFpEF. In other words, it may be
that the increased stiffness of the ascending aorta rather
than the peripheral vasculature is the pathologic mech-
anism which drives the progression from diastolic dys-
function to HFpEF. Prospective studies are needed to
further investigate the contribution of proximal aortic
stiffness to the development of HFpEF.
Strengths
The strengths of our analysis included the longitudinal
nature of the study, which allowed us to investigate
whether increased vascular stiffness precedes the devel-
opment of HFpEF in patients with asymptomatic dia-
stolic dysfunction. In addition, our matched cohort
design allowed us to control for confounding variables
including age, race and gender, all of which are known
to be associated with vascular stiffness [28, 30, 31].
Subjects were also matched for BSA because BSA is a
key determinant of aortic root and arch dimension [32].
In addition, matching allowed us to use a smaller
sample size as compared to an unmatched study. Fur-
thermore, our calculated values for aortic distensibility
and aortic strain were similar to those published in
previous literature, particularly for hypertensive and
diabetic patients [18].
Limitations
The number of subjects and retrospective design are im-
portant limitations of the study and any associations dis-
cussed should be considered in this context. Our sample
size was further limited due to missing data in the ana-
lyzed TTE reports. For instance, 48/77 subjects in Group
1 and 28/77 subjects in Group 2 did not have blood
pressure recordings at the time of their echocardiogram,
Table 6 Echocardiographic markers of vascular stiffness for
diabetic subset
Variable Group 1: Diabetic








2.2 ± 0.6 - (14) 1.7 ± 0.6 - (9) 0.051
Arterial Elastance ±
mmHg/mL)
1.9 ± 0.4 - (14) 1.7 ± 0.3 - (9) 0.098
Aortic Strain (%) 6.9 ± 3.3 - (43) 9.7 ± 5.6 - (9) 0.02
Aortic Distensibility
(cm2dyne−110−3)
1.8 ± 1.0 - (17) 3.5 ± 2.6 - (14) 0.02
Note: All data expressed as mean ± standard deviation. Group size is listed
in parentheses
Table 5 Baseline characteristics for diabetic subset
Variable Group 1: Diabetic







Age (years) 66.0 ± 9.40 66.9 ± 10.2 0.73
Gender (% Female) 65.1 71.4 0.61
Race (% African American) 34.9 28.6 0.61
Body Surface Area (m2) 2.0 ± 0.3 2.0 ± 0.2 0.19
Tobacco Use (%) 65.9 66.7 0.95
Alcohol Use (%) 37.5 57.1 0.14




Atrial Fibrillation (%) 30.2 14.3 0.17

















Note: Continuous data expressed as mean ± standard deviation. Categorical
variables expressed as percentage
*p-value calculated using Fisher’s Exact Test for a 2x3 contingency table
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rendering it impossible to calculate all the indices of vas-
cular stiffness for these subjects. We did counter this
limitation by including aortic strain as part of our ana-
lysis, so that at minimum we could assess proximal aor-
tic stiffness in the absence of blood pressure recordings
in all subjects. Despite this, arterial stiffness, arterial
elastance and aortic strain were not significantly corre-
lated with the development of HFpEF. A larger sample
size may be needed to demonstrate statistically signifi-
cant results, particularly in the diabetic sub-group.
Since 2003, the guidelines for assessing and grading
diastolic dysfunction have been updated twice, most re-
cently in 2016 [33]. Therefore, it is possible that some
echocardiograms interpreted as having diastolic dysfunc-
tion or that some studies that were assumed to have
normal diastolic function in 2003 would no longer re-
ceive the same classification under the new guidelines.
However, incorporating peak E and A-wave velocities
and E/A ratio into the determination of diastolic func-
tion has not changed since 2002.
Subjects were not matched for co-morbidities com-
monly seen in HFpEF such as hypertension, DM and
CKD because we wanted to confirm the validity of our
data set by reproducing the previously demonstrated
association between the development of HFpEF and
these co-morbidities. These covariates were adjusted for
in the multiple logistic regression analysis to eliminate
the effect of these variables on HFpEF development.
Conclusions
This study confirmed the previously demonstrated asso-
ciation between the development of HFpEF and the
presence of hypertension, DM, CAD, CKD and AF [5,
11–13]. However, the presence of decreased aortic dis-
tensibility on TTE in patients with diastolic dysfunction
prior to the development of HFpEF is a novel finding.
In summary, these data support the conclusion that
incorporating the simple measurements and calculations
of proximal aortic stiffness, including distensibility and
strain, when diastolic dysfunction is first identified on
TTE may help to identify higher risk patients prior to
the development of HFpEF. Larger prospective studies
are needed to further investigate this relationship and to
determine whether early interventions to control blood
pressure and diabetes can alter the outcome in these
patients.
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